|Videos|May 11, 2016

How Does the Treatment Regimen Differ for Acute HCV vs. Chronic HCV?

Charitha Gowda, MD, MPH, Infectious diseases physician at Penn Presbyterian Medical Center explains how the treatment regimen for treating those with acute hepatitis C differs from chronic hepatitis C.

Charitha Gowda, MD, MPH, Infectious diseases physician at Penn Presbyterian Medical Center explains how the treatment regimen for treating those with acute hepatitis C differs from chronic hepatitis C.


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.